XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.XORTX.com.
View Top Employees from XORTX Therapeutics Inc.| Website | https://www.xortx.com |
| Ticker | XRX |
| Revenue | $26 million |
| Employees | 6 (4 on RocketReach) |
| Address | 3710 33rd Street NW, Calgary, Alberta T2L 2M1, CA |
| Phone | (403) 455-7717 |
| Technologies |
JavaScript,
HTML,
PHP
+19 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Drug Manufacturing & Research, Biopharma, Pharmaceuticals, Biotechnology, Healthcare, Health Care, Science and Engineering, Pharmaceutical, Therapeutics |
| Competitors | BerGenBio ASA, Brickell Biotech, Inc., Destiny Pharma plc, Parion Sciences, Rexahn Pharmaceuticals |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 32541 Companies |
Looking for a particular XORTX Therapeutics Inc. employee's phone or email?
XORTX Therapeutics Inc. Questions
The XORTX Therapeutics Inc. annual revenue was $26 million in 2024.
Amar Keshri is the CFO of XORTX Therapeutics Inc..
4 people are employed at XORTX Therapeutics Inc..
XORTX Therapeutics Inc. is based in Calgary, Alberta.
The NAICS codes for XORTX Therapeutics Inc. are [32, 325, 3254, 541, 54, 32541].
The SIC codes for XORTX Therapeutics Inc. are [283, 28].
Top XORTX Therapeutics Inc. Employees
-
45
-
1
Related Companies
